Free tool
FAERS Monitor: Beqalzi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 220711 or its brand name (Beqalzi, Sonrotoclax). Reports on generic versions are filed under their own applications.
Reports
16
Serious
15
94% of reports
Hospitalization
7
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use7
- acute kidney injury3
- disease progression3
- myelosuppression3
- white blood cell count decreased3
- neutrophil count decreased2
- pneumonia2
- rhinovirus infection2
- acute myeloid leukaemia1
- adverse event1
- agranulocytosis1
- anaemia1
- arrhythmia1
- atrial flutter1
- back pain1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 6 |
| 2026 | 10 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,143 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| rhinovirus infection | 2 | 675.9 | 184.8 | 757 |
| atrial flutter | 1 | 164.7 | 24.7 | 40 |
| myelosuppressionSignal | 3 | 109.5 | 39.5 | 224 |
| acute myeloid leukaemia | 1 | 84.4 | 12.6 | 20 |
| agranulocytosis | 1 | 70.7 | 10.6 | 17 |
| neutrophil count decreased | 2 | 64.5 | 17.6 | 70 |
| white blood cell count decreasedSignal | 3 | 36.4 | 13.1 | 71 |
| disease progressionSignal | 3 | 33.3 | 12.0 | 65 |
| arrhythmia | 1 | 27.8 | 4.2 | 6 |
| acute kidney injurySignal | 3 | 25.8 | 9.3 | 49 |
| adverse event | 1 | 14.3 | 2.1 | 3 |
| off label useSignal | 7 | 10.5 | 6.0 | 53 |
| pneumonia | 2 | 8.1 | 2.2 | 6 |
| anaemia | 1 | 6.9 | 1.0 | 1 |
| back pain | 1 | 5.7 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.